Back to Journals » Cancer Management and Research » Volume 13
microRNA-548b Suppresses Aggressive Phenotypes of Hepatocellular Carcinoma by Directly Targeting High-Mobility Group Box 1 mRNA [Retraction]
Yun Z, Meng F, Jiang P, Yue M, Li S. Cancer Manag Res. 2019;11:5821–5834.
The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised over alleged image duplication in Figures 6D and 8A with similar images from unrelated articles, specifically:
- Figure 6D, panel Hep3B 1 appears to have been duplicated with a similar image in Figure 5D from Chen et al, 2019 (https://doi.org/10.2147/OTT.S192137).
- Figure 6D, panel SK-HEP-1 6 appears to have been duplicated with a similar image in Figure 6D from Liu et al, 2019 (https://doi.org/10.3892/ijo.2019.4735).
- Figure 8A, panels NC mimics 2 and miR-548b mimics 2 appear to have been duplicated with similar images in Figure 8A from Song et al, 2019 (https://doi.org/10.2147/OTT.S201282).
The authors responded to our queries but were unable to provide a satisfactory explanation for the alleged duplication and could not provide satisfactory original data for their study. The Editor advised for the article to be retracted.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.